Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10548875	JOURNEY	Glycopyrrolate salts	Feb, 2033 (8 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6433003	JOURNEY	Method for treating hyperhidrosis in mammals	Apr, 2020 (4 years ago)
US10052267	JOURNEY	Topical glycopyrrolate formulations	Oct, 2028 (4 years from now)
US8618160	JOURNEY	Topical glycopyrrolate formulations	Dec, 2029 (5 years from now)
US9744105	JOURNEY	Topical glycopyrrolate formulations	Jul, 2030 (6 years from now)
US10543192	JOURNEY	Glycopyrrolate salts	Feb, 2033 (8 years from now)
US10004717	JOURNEY	Glycopyrrolate salts	Feb, 2033 (8 years from now)
US9006462	JOURNEY	Glycopyrrolate salts	Feb, 2033 (8 years from now)
US8859610	JOURNEY	Crystalline glycopyrrolate tosylate	Feb, 2033 (8 years from now)
US9259414	JOURNEY	Glycopyrrolate salts	Feb, 2033 (8 years from now)

Qbrexza is owned by Journey.

Qbrexza contains Glycopyrronium Tosylate.

Qbrexza has a total of 10 drug patents out of which 1 drug patent has expired.

Expired drug patents of Qbrexza are:

Qbrexza was authorised for market use on 28 June, 2018.

Qbrexza is available in cloth;topical dosage forms.

Qbrexza can be used as topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.

The generics of Qbrexza are possible to be released after 28 February, 2033.

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 28, 2021

Market Authorisation Date: 28 June, 2018

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: CLOTH;TOPICAL

Qbrexza patents expiration